Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| AGIOS PHARMACEUTICALS, INC.AGIO · Entity 4499 | Director | July 08, 2026 | July 10, 2026 |
| Disc Medicine, Inc.IRON · Entity 2273 | Director | December 29, 2022 | January 03, 2023 |
| Scholar Rock Holding CorpSRRK · Entity 3721 | Director · CHIEF EXECUTIVE OFFICER | March 10, 2025 | March 12, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
AGIOS PHARMACEUTICALS, INC.
Report date July 08, 2026 · Filed July 10, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common stockSEC Table I · non-derivative | Direct | 1,447 |
Reported balance
After 2026-07-08 transaction · row 1
1 source rowRow 1 · 2026-07-08 · Grant · Acquired 1,447 · Balance 1,447 |
| Restricted stock unitsSEC Table II · derivative / convertible security | Direct | 2,894 |
Reported balance
After 2026-07-08 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-07-08 · Exercise / conversion · Disposed 1,447 · Balance 2,894 F1: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F2: The restricted stock units were granted on July 8, 2025. Beginning on July 8, 2026, the shares underlying the restricted stock units will vest in three equal annual installments. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.
F2: The restricted stock units were granted on July 8, 2025. Beginning on July 8, 2026, the shares underlying the restricted stock units will vest in three equal annual installments.
Disc Medicine, Inc.
Report date December 29, 2022 · Filed January 03, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.50 · Expires 2032-12-28 | Direct | 7,000 |
Reported balance
After 2022-12-29 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-12-29 · Grant · Acquired 7,000 · Balance 7,000 F1: The shares underlying this option vest upon the first to occur of (i) the date of the Company's 2023 annual meeting of its stockholders, or (ii) the one-year anniversary of the grant date, subject to the Reporting Person's continued service on each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares underlying this option vest upon the first to occur of (i) the date of the Company's 2023 annual meeting of its stockholders, or (ii) the one-year anniversary of the grant date, subject to the Reporting Person's continued service on each such vesting date.
Scholar Rock Holding Corp
Report date March 10, 2025 · Filed March 12, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 425,561 |
Reported balance
After 2025-03-10 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2025-03-10 · Grant · Acquired 113,570 · Balance 425,561 F1: Each restricted stock unit ("RSU") represents the contingent right to receive, upon vesting of the RSU, one share of the Issuer's common stock. The shares subject to this RSU vest in four annual installments over four years, with the first annual installment to vest on February 15, 2026 and each additional installment to vest annually thereafter; provided the reporting person continues to have a service relationship with the Issuer on such vesting date. F2: Consists of 76,277 shares of common stock and 349,284 RSUs |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $35.15 · Expires 2035-03-10 | Direct | 151,430 |
Reported balance
After 2025-03-10 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-03-10 · Grant · Acquired 151,430 · Balance 151,430 F3: Options to vest in sixteen quarterly installments over four years, with the first quarterly installment to vest on April 1, 2025 and each additional installment to vest quarterly thereafter; provided the individual continues to have a service relationship with the Issuer on such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit ("RSU") represents the contingent right to receive, upon vesting of the RSU, one share of the Issuer's common stock. The shares subject to this RSU vest in four annual installments over four years, with the first annual installment to vest on February 15, 2026 and each additional installment to vest annually thereafter; provided the reporting person continues to have a service relationship with the Issuer on such vesting date.
F2: Consists of 76,277 shares of common stock and 349,284 RSUs
F3: Options to vest in sixteen quarterly installments over four years, with the first quarterly installment to vest on April 1, 2025 and each additional installment to vest quarterly thereafter; provided the individual continues to have a service relationship with the Issuer on such vesting date.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
ACCELERON PHARMA INC
Report date November 19, 2021 · Filed November 22, 2021
Section 16 reporting ended · disclosed 2021-11-22. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2021-11-19 transaction · row 1
1 source rowRow 1 · 2021-11-19 · Other · Disposed 21,233 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of September 29, 2021, by and among the Issuer, Merck Sharp & Dohme Corp. ("Parent"), and Astros Merger Sub, Inc., a direct wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effective as of November 19, 2021 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $180.00 in cash (the "Offer Price") without interest and subject to applicable withholding taxes. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $52.61 | Direct | 0 |
Reported balance
After 2021-11-19 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2021-11-19 · Disposition to issuer · Disposed 96,963 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $115.53 | Direct | 0 |
Reported balance
After 2021-11-19 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2021-11-19 · Disposition to issuer · Disposed 20,896 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of September 29, 2021, by and among the Issuer, Merck Sharp & Dohme Corp. ("Parent"), and Astros Merger Sub, Inc., a direct wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effective as of November 19, 2021 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $180.00 in cash (the "Offer Price") without interest and subject to applicable withholding taxes.
F2: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option.
LAVA Therapeutics NV
Report date November 13, 2025 · Filed November 17, 2025
Section 16 reporting ended · disclosed 2025-11-17. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Share Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.93 · Expires 2035-02-12 | Direct | 0 |
Reported balance
After 2025-11-13 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-11-13 · Disposition to issuer · Disposed 33,390 · Balance 0 F1: This option was cancelled pursuant to that certain Purchase Agreement, dated August 3, 2025, by and between the Issuer and XOMA Royalty Corporation (as amended, the "Purchase Agreement") in exchange for cash and contingent value rights ("CVRs") (without interest and net of applicable withholding tax and other applicable deductions) in an amount equal to (i) the excess of $1.04 over the per share exercise price of such option multiplied by the total number of shares underlying such in option and (ii) one CVR per share underlying such in-the-money option. |
Filing footnotes · ownership attribution and instrument terms
F1: This option was cancelled pursuant to that certain Purchase Agreement, dated August 3, 2025, by and between the Issuer and XOMA Royalty Corporation (as amended, the "Purchase Agreement") in exchange for cash and contingent value rights ("CVRs") (without interest and net of applicable withholding tax and other applicable deductions) in an amount equal to (i) the excess of $1.04 over the per share exercise price of such option multiplied by the total number of shares underlying such in option and (ii) one CVR per share underlying such in-the-money option.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 08, 2026 Filed Jul 10, 2026 16:18 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionRestricted stock units · Derivative | 1,447 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-26-000112 · wk-form4_1783714678.xml · derivative · entry 2 Backstrom Jay T. · CIK 0001796398 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,894 Underlying: Common stock · 1,447 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F2 · derivative.exercise_date: The restricted stock units were granted on July 8, 2025. Beginning on July 8, 2026, the shares underlying the restricted stock units will vest in three equal annual installments. F2 · derivative.expiration_date: The restricted stock units were granted on July 8, 2025. Beginning on July 8, 2026, the shares underlying the restricted stock units will vest in three equal annual installments. Read SEC document |
| July 08, 2026 Filed Jul 10, 2026 16:18 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | GrantCommon stock | 1,447 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-26-000112 · wk-form4_1783714678.xml · nonDerivative · entry 1 Backstrom Jay T. · CIK 0001796398 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,447 Read SEC document |
| June 18, 2026 Filed Jun 23, 2026 21:12 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | GrantStock options (right to buy) · Derivative | 14,950 | $0.00 Strike: $34.16 | $0.00 |
DisclosureSEC source: 0001439222-26-000079 · wk-form4_1782249139.xml · derivative · entry 2 Backstrom Jay T. · CIK 0001796398 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,950 Underlying: Common stock · 14,950 shares Expires 2036-06-18 F3 · derivative.exercise_date: These options were granted on June 18, 2026. The shares underlying these options vest as to 100% of the underlying shares on June 18, 2027. Read SEC document |
| June 18, 2026 Filed Jun 23, 2026 21:12 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | GrantRestricted stock units · Derivative | 2,927 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-26-000079 · wk-form4_1782249139.xml · derivative · entry 1 Backstrom Jay T. · CIK 0001796398 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,927 Underlying: Common stock · 2,927 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F2 · derivative.exercise_date: The restricted stock units were granted on June 18, 2026. The shares underlying the stock units will vest in full on June 18, 2027. Vested shares will be delivered to the reporting person within three business days after such shares become vested. F2 · derivative.expiration_date: The restricted stock units were granted on June 18, 2026. The shares underlying the stock units will vest in full on June 18, 2027. Vested shares will be delivered to the reporting person within three business days after such shares become vested. Read SEC document |
| November 13, 2025 Filed Nov 17, 2025 21:30 UTC | LAVA Therapeutics NV LVTX · Entity 73047 | Disposition to issuerShare Options (Right to Buy) · Derivative | 33,390 | $0.00 Strike: $0.93 | $0.00 |
DisclosureSEC source: 0001796398-25-000004 · form4-11172025_041109.xml · derivative · entry 1 Backstrom Jay T. · CIK 0001796398 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 33,390 shares Expires 2035-02-12 F1 · derivative.exercise_date: This option was cancelled pursuant to that certain Purchase Agreement, dated August 3, 2025, by and between the Issuer and XOMA Royalty Corporation (as amended, the "Purchase Agreement") in exchange for cash and contingent value rights ("CVRs") (without interest and net of applicable withholding tax and other applicable deductions) in an amount equal to (i) the excess of $1.04 over the per share exercise price of such option multiplied by the total number of shares underlying such in option and (ii) one CVR per share underlying such in-the-money option. Read SEC document |
| July 08, 2025 Filed Jul 10, 2025 20:14 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | GrantRestricted stock units · Derivative | 4,341 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-25-000080 · wk-form4_1752178459.xml · derivative · entry 2 Backstrom Jay T. · CIK 0001796398 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,341 Underlying: Common stock · 4,341 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F3 · derivative.exercise_date: The restricted stock units were granted on July 8, 2025. Beginning on July 8, 2026, the shares underlying the restricted stock units will vest in three equal annual installments. F3 · derivative.expiration_date: The restricted stock units were granted on July 8, 2025. Beginning on July 8, 2026, the shares underlying the restricted stock units will vest in three equal annual installments. Read SEC document |
| July 08, 2025 Filed Jul 10, 2025 20:14 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | GrantStock options (right to buy) · Derivative | 23,393 | $0.00 Strike: $36.28 | $0.00 |
DisclosureSEC source: 0001439222-25-000080 · wk-form4_1752178459.xml · derivative · entry 1 Backstrom Jay T. · CIK 0001796398 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,393 Underlying: Common stock · 23,393 shares Expires 2035-07-08 F1 · derivative.exercise_date: This option was granted on July 8, 2025. The shares underlying this option vest as to 25% of the underlying shares on July 8, 2026, with the remaining 75% vesting in 36 equal monthly installments thereafter. Read SEC document |
| March 10, 2025 Filed Mar 12, 2025 21:00 UTC | Scholar Rock Holding Corp SRRK · Entity 3721 | GrantStock Option (Right to Buy) · Derivative | 151,430 | $0.00 Strike: $35.15 | $0.00 |
DisclosureSEC source: 0001415889-25-007839 · form4-03122025_050311.xml · derivative · entry 2 Backstrom Jay T. · CIK 0001796398 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 151,430 Underlying: Common Stock · 151,430 shares Expires 2035-03-10 F3 · derivative.exercise_date: Options to vest in sixteen quarterly installments over four years, with the first quarterly installment to vest on April 1, 2025 and each additional installment to vest quarterly thereafter; provided the individual continues to have a service relationship with the Issuer on such vesting date. Read SEC document |
| March 10, 2025 Filed Mar 12, 2025 21:00 UTC | Scholar Rock Holding Corp SRRK · Entity 3721 | GrantCommon Stock | 113,570 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-007839 · form4-03122025_050311.xml · nonDerivative · entry 1 Backstrom Jay T. · CIK 0001796398 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 425,561 F1 · shares: Each restricted stock unit ("RSU") represents the contingent right to receive, upon vesting of the RSU, one share of the Issuer's common stock. The shares subject to this RSU vest in four annual installments over four years, with the first annual installment to vest on February 15, 2026 and each additional installment to vest annually thereafter; provided the reporting person continues to have a service relationship with the Issuer on such vesting date. F2 · balance_after: Consists of 76,277 shares of common stock and 349,284 RSUs Read SEC document |
| February 18, 2025 Filed Feb 20, 2025 22:41 UTC | Scholar Rock Holding Corp SRRK · Entity 3721 | SaleCommon Stock | 18,372 | $36.83 | $676,622.39 |
DisclosureSEC source: 0001415889-25-004915 · form4-02202025_100247.xml · nonDerivative · entry 1 Backstrom Jay T. · CIK 0001796398 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 311,991 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of restricted stock units ("RSU") on February 15, 2025. This sale is mandated by the Issuer's election under its equity incentive plans to require the reporting person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the reporting person. The shares vested pursuant to awards that were granted on February 13, 2023. Each RSU represents the contingent right to receive upon vesting of the RSU, one share of the Issuer's common stock. The shares subject to these RSU awards vest annually over four years, subject to a continued service relationship with the Issuer on the applicable vesting date. F2 · balance_after: Consists of 76,277 shares of common stock and 235,714 RSUs. Read SEC document |
| February 13, 2025 Filed Feb 19, 2025 01:15 UTC | LAVA Therapeutics NV LVTX · Entity 73047 | GrantCommon Shares (Right to Buy) · Derivative | 33,390 | $0.00 Strike: $0.93 | $0.00 |
DisclosureSEC source: 0001415889-25-004528 · form4-02182025_080212.xml · derivative · entry 1 Backstrom Jay T. · CIK 0001796398 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,390 Underlying: Common Shares · 33,390 shares Expires 2035-02-12 F1 · derivative.exercise_date: 100% of the shares underlying the option will vest on February 13, 2026, provided the Reporting Person remains in a service relationship with the Issuer or a subsidiary of the Issuer on such vesting date. Read SEC document |
| January 16, 2025 Filed Jan 21, 2025 21:35 UTC | Scholar Rock Holding Corp SRRK · Entity 3721 | SaleCommon Stock | 22,308 | $44.20 | $985,951.14 |
DisclosureSEC source: 0001415889-25-001795 · form4-01212025_040115.xml · nonDerivative · entry 1 Backstrom Jay T. · CIK 0001796398 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 330,363 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of restricted stock units ("RSU") on January 15, 2025. This sale is mandated by the Issuer's election under its equity incentive plans to require the reporting person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the reporting person. The shares vested pursuant to awards that were granted on February 12, 2024. Each RSU represents the contingent right to receive upon vesting of the RSU, one share of the Issuer's common stock. The shares subject to these RSU awards vest annually over four years, subject to a continued service relationship with the Issuer on the applicable vesting date. F2 · balance_after: Consists of 57,149 shares of common stock and 273,214 RSUs. Read SEC document |
| February 16, 2024 Filed Feb 20, 2024 21:46 UTC | Scholar Rock Holding Corp SRRK · Entity 3721 | SaleCommon Stock | 11,614 | $15.74 | $182,841.52 |
DisclosureSEC source: 0001415889-24-004379 · form4-02202024_090207.xml · nonDerivative · entry 1 Backstrom Jay T. · CIK 0001796398 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 352,671 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of restricted stock units ("RSU") on February 15, 2024. This sale is mandated by the Issuer's election under its equity incentive plans to require the reporting person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the reporting person. The shares vested pursuant to awards that were granted on February 13, 2023. Each RSU represents the contingent right to receive upon vesting of the RSU, one share of the Issuer's common stock. The shares subject to these RSU awards vest annually over four years, subject to a continued service relationship with the Issuer on the applicable vesting date. F2 · balance_after: Consists of 25,886 shares of common stock and 326,785 RSUs. Read SEC document |
| February 12, 2024 Filed Feb 14, 2024 00:17 UTC | Scholar Rock Holding Corp SRRK · Entity 3721 | GrantStock Option (Right to Buy) · Derivative | 285,715 | $0.00 Strike: $15.75 | $0.00 |
DisclosureSEC source: 0001415889-24-003630 · form4-02142024_120208.xml · derivative · entry 2 Backstrom Jay T. · CIK 0001796398 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 285,715 Underlying: Common Stock · 285,715 shares Expires 2034-02-12 F3 · derivative.exercise_date: Options to vest in sixteen quarterly installments over four years, with the first quarterly installment to vest on April 1, 2024 and each additional installment to vest quarterly thereafter; provided the individual continues to have a service relationship with the Issuer on such vesting date. Read SEC document |
| February 12, 2024 Filed Feb 14, 2024 00:17 UTC | Scholar Rock Holding Corp SRRK · Entity 3721 | GrantCommon Stock | 214,285 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-003630 · form4-02142024_120208.xml · nonDerivative · entry 1 Backstrom Jay T. · CIK 0001796398 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 364,285 F1 · shares: Each restricted stock unit ("RSU") represents the contingent right to receive, upon vesting of the RSU, one share of the Issuer's common stock. The shares subject to this RSU vest in four annual installments over four years, with the first annual installment to vest on January 15, 2025 and each additional installment to vest annually thereafter; provided the reporting person continues to have a service relationship with the Issuer on such vesting date. F2 · balance_after: Consists solely of RSUs. Read SEC document |
| February 13, 2023 Filed Feb 15, 2023 21:37 UTC | Scholar Rock Holding Corp SRRK · Entity 3721 | GrantStock Option (Right to Buy) · Derivative | 200,000 | $0.00 Strike: $10.00 | $0.00 |
DisclosureSEC source: 0001415889-23-002611 · form4-02152023_090222.xml · derivative · entry 2 Backstrom Jay T. · CIK 0001796398 · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2033-02-13 F2 · derivative.exercise_date: Options to vest in sixteen quarterly installments over four years, with the first quarterly installment to vest on April 1, 2023 and each additional installment to vest quarterly thereafter; provided the individual continues to have a service relationship with the Issuer on such vesting date. Read SEC document |
| February 13, 2023 Filed Feb 15, 2023 21:37 UTC | Scholar Rock Holding Corp SRRK · Entity 3721 | GrantCommon Stock | 150,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-002611 · form4-02152023_090222.xml · nonDerivative · entry 1 Backstrom Jay T. · CIK 0001796398 · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 F1 · shares: Each restricted stock unit ("RSU") represents the contingent right to receive, upon vesting of the RSU, one share of the Issuer's common stock. The shares subject to this RSU vest in four annual installments over four years, with the first annual installment to vest on February 15, 2024 and each additional installment to vest annually thereafter; provided the reporting person continues to have a service relationship with the Issuer on such vesting date. Read SEC document |
| December 29, 2022 Filed Jan 3, 2023 22:05 UTC | Disc Medicine, Inc. IRON · Entity 2273 | GrantStock Option (Right to Buy) · Derivative | 7,000 | $0.00 Strike: $13.50 | $0.00 |
DisclosureSEC source: 0000899243-23-000296 · doc4.xml · derivative · entry 1 Backstrom Jay T. · CIK 0001796398 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,000 Underlying: Common Stock · 7,000 shares Expires 2032-12-28 F1 · derivative.exercise_date: The shares underlying this option vest upon the first to occur of (i) the date of the Company's 2023 annual meeting of its stockholders, or (ii) the one-year anniversary of the grant date, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| September 20, 2022 Filed Sep 22, 2022 20:16 UTC | Scholar Rock Holding Corp SRRK · Entity 3721 | GrantStock Option (right to buy) · Derivative | 1,000,000 | $0.00 Strike: $8.85 | $0.00 |
DisclosureSEC source: 0001104659-22-102341 · tm2226370-2_4seq1.xml · derivative · entry 1 Backstrom Jay T. · CIK 0001796398 · CEO-Elect 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,000,000 Underlying: Common Stock · 1,000,000 shares Expires 2032-09-20 F1 · derivative.exercise_date: Options vest over four years with 25% vesting on September 20, 2023 and the remainder vesting in 12 quarterly installments thereafter, provided the reporting person continues to have a service relationship with the Issuer on such applicable vesting date. Read SEC document |
| November 19, 2021 Filed Nov 22, 2021 14:04 UTC | ACCELERON PHARMA INC XLRN · Entity 15780 | Disposition to issuerOption to Purchase Common Stock · Derivative | 20,896 | Not disclosed Strike: $115.53 | Not disclosed |
DisclosureSEC source: 0001104659-21-142267 · tm2133601-3_4seq1.xml · derivative · entry 3 Backstrom Jay T. · CIK 0001796398 · EVP, Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,896 shares Expires not disclosed F2 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option. F2 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option. F2 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option. Read SEC document |
| November 19, 2021 Filed Nov 22, 2021 14:04 UTC | ACCELERON PHARMA INC XLRN · Entity 15780 | Disposition to issuerOption to Purchase Common Stock · Derivative | 96,963 | Not disclosed Strike: $52.61 | Not disclosed |
DisclosureSEC source: 0001104659-21-142267 · tm2133601-3_4seq1.xml · derivative · entry 2 Backstrom Jay T. · CIK 0001796398 · EVP, Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 96,963 shares Expires not disclosed F2 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option. F2 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option. F2 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option. Read SEC document |
| November 19, 2021 Filed Nov 22, 2021 14:04 UTC | ACCELERON PHARMA INC XLRN · Entity 15780 | OtherCommon Stock | 21,233 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-21-142267 · tm2133601-3_4seq1.xml · nonDerivative · entry 1 Backstrom Jay T. · CIK 0001796398 · EVP, Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of September 29, 2021, by and among the Issuer, Merck Sharp & Dohme Corp. ("Parent"), and Astros Merger Sub, Inc., a direct wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effective as of November 19, 2021 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $180.00 in cash (the "Offer Price") without interest and subject to applicable withholding taxes. F1 · shares: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of September 29, 2021, by and among the Issuer, Merck Sharp & Dohme Corp. ("Parent"), and Astros Merger Sub, Inc., a direct wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effective as of November 19, 2021 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $180.00 in cash (the "Offer Price") without interest and subject to applicable withholding taxes. F1 · price: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of September 29, 2021, by and among the Issuer, Merck Sharp & Dohme Corp. ("Parent"), and Astros Merger Sub, Inc., a direct wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effective as of November 19, 2021 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $180.00 in cash (the "Offer Price") without interest and subject to applicable withholding taxes. Read SEC document |
| January 29, 2021 Filed Feb 3, 2021 00:15 UTC | ACCELERON PHARMA INC XLRN · Entity 15780 | GrantOption to Purchase Common Stock · Derivative | 20,896 | $0.00 Strike: $115.53 | $0.00 |
DisclosureSEC source: 0001179110-21-001117 · edgar.xml · derivative · entry 2 Backstrom Jay T. · CIK 0001796398 · EVP, Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,896 Underlying: Common Stock · 20,896 shares Expires 2031-01-29 F1 · derivative.exercise_date: The shares of common stock underlying this stock option award vest in equal quarterly installments over the four years after January 1, 2021. Read SEC document |
| January 29, 2021 Filed Feb 3, 2021 00:15 UTC | ACCELERON PHARMA INC XLRN · Entity 15780 | GrantCommon Stock | 5,409 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-21-001117 · edgar.xml · nonDerivative · entry 1 Backstrom Jay T. · CIK 0001796398 · EVP, Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,781 Read SEC document |
| January 04, 2021 Filed Jan 7, 2021 00:05 UTC | ACCELERON PHARMA INC XLRN · Entity 15780 | Tax withholdingCommon Stock | 1,735 | $124.31 | $215,677.85 |
DisclosureSEC source: 0001179110-21-000366 · edgar.xml · nonDerivative · entry 1 Backstrom Jay T. · CIK 0001796398 · EVP, Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,372 Read SEC document |
| January 02, 2020 Filed Jan 4, 2020 02:32 UTC | ACCELERON PHARMA INC XLRN · Entity 15780 | GrantOption to Purchase Common Stock · Derivative | 94,865 | $0.00 Strike: $52.61 | $0.00 |
DisclosureSEC source: 0001179110-20-000268 · edgar.xml · derivative · entry 2 Backstrom Jay T. · CIK 0001796398 · EVP, Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,865 Underlying: Common Stock · 94,865 shares Expires 2030-01-02 F1 · derivative.exercise_date: The shares of common stock underlying this stock option award vest as to 25% of the shares on the first anniversary of January 1, 2020 and the remaining shares vest in equal quarterly installments over the following three years thereafter. Read SEC document |
| January 02, 2020 Filed Jan 4, 2020 02:32 UTC | ACCELERON PHARMA INC XLRN · Entity 15780 | GrantCommon Stock | 17,107 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-000268 · edgar.xml · nonDerivative · entry 1 Backstrom Jay T. · CIK 0001796398 · EVP, Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,107 Read SEC document |
| January 02, 2020 Filed Feb 10, 2020 23:01 UTC Amendment | ACCELERON PHARMA INC XLRN · Entity 15780 | GrantOption to Purchase Common Stock · Derivative | 96,963 | $0.00 Strike: $52.61 | $0.00 |
DisclosureSEC source: 0001179110-20-001410 · edgar.xml · derivative · entry 1 Backstrom Jay T. · CIK 0001796398 · EVP, Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,963 Underlying: Common Stock · 96,963 shares Expires 2030-01-02 F1 · shares: Due to a clerical error, the original Form 4 filed on January 3, 2020 listed the incorrect number of securities in columns 5, 7 and 9 of Table II. F2 · derivative.exercise_date: The shares of common stock underlying this stock option award vest as to 25% of the shares on the first anniversary of January 1, 2020 and the remaining shares vest in equal quarterly installments over the following three years thereafter. F1 · derivative.underlying_shares: Due to a clerical error, the original Form 4 filed on January 3, 2020 listed the incorrect number of securities in columns 5, 7 and 9 of Table II. F1 · balance_after: Due to a clerical error, the original Form 4 filed on January 3, 2020 listed the incorrect number of securities in columns 5, 7 and 9 of Table II. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.